Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
Exp Cell Res ; 367(2): 282-290, 2018 06 15.
Artículo en Inglés | MEDLINE | ID: mdl-29649428

RESUMEN

BACKGROUND: Annexin A1 (ANXA1) and Translocator Protein-18KDa (TSPO) down-regulate neuroinflammation. We investigated the role of recombinant ANXA1 (rANXA) on TSPO functions on Toll Like Receptor (TLR) activated microglia. METHODS: BV-2 cells (murine microglia), were stimulated by E. coli Lipopolysaccharide (LPS) and treated with rANXA1 in order to measure TSPO expression and inflammatory parameters. Anti-sense ANXA1 and TLR4 and TSPO shRNA, as well as pharmacological treatments, were employed to assess the mechanisms involved. RESULTS: LPS-stimulated BV-2 cells caused overexpression of TSPO, which was inhibited by: pharmacological blockade of TLR4 or TLR4 mRNA silencing; inhibition of myeloid differentiation primary response gene 88 (MyD88) dimerization; or blocking of nuclear factor κB (NF-κB) activation. rANXA1 treatment impaired LPS-induced TSPO upregulation by down-modulating MyD88 and NF-κB signaling; the effect was abolished by WRW4, an antagonist of formyl peptide receptor 2 (FPR2). rANXA1 treatment also downregulated interleukin 1ß (IL-1ß) and tumor necrosis factor-α (TNFα) secretion in LPS-stimulated BV-2 cells. TSPO knockdown in BV-2 cells augmented LPS-induced TNFα secretion and abolished the inhibitory effect of rANXA1 on TNFα secretion evoked by LPS. CONCLUSIONS: exogenous ANXA1 down-modulates LPS-induced TSPO via MyD-88/NF-κB pathways, and constitutive TSPO is pivotal for the control of ANXA1 on TNFα secretion. TSPO actions may be involved with the mechanisms of ANXA1 on inflammatory brain diseases.


Asunto(s)
Anexina A1/fisiología , Receptores de GABA/metabolismo , Animales , Anexina A1/metabolismo , Línea Celular , Citocinas/metabolismo , Humanos , Lipopolisacáridos/farmacología , Ratones , Receptores de Formil Péptido/fisiología , Transducción de Señal , Receptor Toll-Like 4/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo
2.
Int J Nanomedicine ; 11: 1261-79, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27099491

RESUMEN

Melanoma is a severe metastatic skin cancer with poor prognosis and no effective treatment. Therefore, novel therapeutic approaches using nanotechnology have been proposed to improve therapeutic effectiveness. Lipid-core nanocapsules (LNCs), prepared with poly(ε-caprolactone), capric/caprylic triglyceride, and sorbitan monostearate and stabilized by polysorbate 80, are efficient as drug delivery systems. Here, we investigated the effects of acetyleugenol-loaded LNC (AcE-LNC) on human SK-Mel-28 melanoma cells and its therapeutic efficacies on melanoma induced by B16F10 in C57B6 mice. LNC and AcE-LNC had z-average diameters and zeta potential close to 210 nm and -10.0 mV, respectively. CytoViva(®) microscopy images showed that LNC and AcE-LNC penetrated into SK-Mel-28 cells, and remained in the cytoplasm. AcE-LNC in vitro treatment (18-90×10(9) particles/mL; 1 hour) induced late apoptosis and necrosis; LNC and AcE-LNC (3-18×10(9) particles/mL; 48 hours) treatments reduced cell proliferation and delayed the cell cycle. Elevated levels of nitric oxide were found in supernatant of LNC and AcE-LNC, which were not dependent on nitric oxide synthase expressions. Daily intraperitoneal or oral treatment (days 3-10 after tumor injection) with LNC or AcE-LNC (1×10(12) particles/day), but not with AcE (50 mg/kg/day, same dose as AcE-LNC), reduced the volume of the tumor; nevertheless, intraperitoneal treatment caused toxicity. Oral LNC treatment was more efficient than AcE-LNC treatment. Moreover, oral treatment with nonencapsulated capric/caprylic triglyceride did not inhibit tumor development, implying that nanocapsule supramolecular structure is important to the therapeutic effects. Together, data herein presented highlight the relevance of the supramolecular structure of LNCs to toxicity on SK-Mel-28 cells and to the therapeutic efficacy on melanoma development in mice, conferring novel therapeutic mechanisms to LNC further than a drug delivery system.


Asunto(s)
Apoptosis/efectos de los fármacos , Adhesión Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Lípidos/química , Melanoma/tratamiento farmacológico , Nanocápsulas/administración & dosificación , Animales , Movimiento Celular/efectos de los fármacos , Sistemas de Liberación de Medicamentos , Citometría de Flujo , Humanos , Masculino , Melanoma/patología , Ratones , Ratones Endogámicos C57BL , Nanocápsulas/química , Poliésteres/química , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
3.
Rev. Hosp. Clin. Fac. Med. Univ. Säo Paulo ; 50(1): 80-9, jan.-fev. 1995. tab
Artículo en Portugués | LILACS | ID: lil-154000

RESUMEN

Os autores realizam uma revisäo sobre o papel de moléculas de adesäo sobre o desenvolvimento da resposta inflamatória, e mostram como a recente descriçäi dessas estruturas, expressas nas membranas dos leucócitos circulantes e da célula endotelial, têm esclarecido os processos de interaçäo leucócito-endotélio, fundamentais apra o recrutamento leucocitário. É discutido ainda, a açäo das principais drogas antiinflamatórias sobre a expressäo e funçäo dessas moléculas de adesäo e finalizando, é destacado o estudo de terapias anti-adesivas, como novas abordagens terapêuticas para o tratamento de doenças inflamatórias


Asunto(s)
Humanos , Inflamación/fisiopatología , Moléculas de Adhesión Celular/fisiología , Antiinflamatorios/uso terapéutico , Inmunoglobulinas/fisiología , Inflamación/tratamiento farmacológico , Integrinas/fisiología , Moléculas de Adhesión Celular/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA